ALX Oncology's $147.2 Million Cash Pool Is Expected To Fund Operations Into 2028

Breast-cancer trial results are expected in the second half of 2027; an earlier solid-tumor readout is due in December.

Share
ALX Oncology's $147.2 Million Cash Pool Is Expected To Fund Operations Into 2028

ALX Oncology, which is testing cancer therapies, said Monday its $147.2 million in cash and investments should fund planned operations through the first half of 2028. The estimate in its earnings disclosure extends beyond the breast-cancer trial results management expects in the second half of 2027.

Cash Covers The Planned Readouts

The cash, cash equivalents and investments were measured at September 30, up from $48.3 million at December 31, 2025. ALX has no products approved for sale, making its available funding central to advancing its clinical programs.

The nearer milestone is ALX2004: management expects safety and early effectiveness findings in December 2026 from an early-stage trial in advanced or metastatic solid tumors expressing EGFR. ALX plans an expert webinar to discuss results from the 35 patients enrolled so far.

ALX2004 pairs an antibody aimed at EGFR, a protein on some tumors, with a drug payload. Its other candidate, evorpacept, blocks CD47, a protein cancer cells use to evade immune-cell attacks.

Breast-Cancer Enrollment Drives The Next Test

ALX expects results from approximately 120 patients in its mid-stage trial combining evorpacept with trastuzumab and chemotherapy for metastatic HER2-positive breast cancer.

“Enrollment in ASPEN-09-Breast remains robust,” ALX Oncology Chief Executive Officer Jason Lettmann said in the earnings release.

That program draws on gastric and gastroesophageal junction cancer research. In September, ALX announced published trial findings in Nature Medicine showing higher response rates than the control group. The greatest benefit appeared in tumors that retained HER2 expression and had high CD47 expression. ALX said the findings support selecting patients by tumor characteristics, an approach it is pursuing in the breast-cancer trial.

More Shares Shrink Per-Share Loss

Third-quarter net loss narrowed to $21.8 million from $22.1 million a year earlier. Loss per share fell to $0.15 from $0.41, a change ALX attributed mainly to more shares outstanding: the weighted-average count rose to 140,904,752 from 53,577,066.

Adjusted loss was $18.9 million, versus $19.6 million a year earlier. The quarterly adjustment removes stock-based pay and costs associated with the term loan's discount and issuance.

Research spending was little changed at $17.5 million, versus $17.4 million. ALX attributed $1.3 million in added clinical costs to opening trial sites and enrolling patients, while research staffing costs increased $1.0 million. Other research costs fell $2.6 million, largely because the year-earlier period included a $2.5 million development milestone.

Administrative spending rose to $5.5 million from $5.1 million. ALX attributed the increase primarily to staffing costs, partly offset by lower legal and consulting expenses.

For the first nine months, net loss narrowed to $57.7 million from $78.8 million. Research spending over that period fell to $44.2 million from $59.4 million.

December's ALX2004 results are the next scheduled clinical test; ALX's funding estimate reaches through the first half of 2028.

Sources

More on ALX Oncology Holdings

All ALX Oncology Holdings (ALXO) coverage →